Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

A study published this week in the peer-reviewed journal Scientific Reports examined the long-term impacts of having shingles ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

A sign from Delta Air Lines welcomed attendees to "UGM," Epic's annual User Group Meeting at their sprawling headquarters in ...

FOX 32's Elizabeth Matthews shares her painful and vision-threatening battle with shingles on her face and eye to raise awareness that the illness can strike younger, healthy adults.

The recombinant herpes zoster vaccine (Shingrix) was not only associated with a reduced risk of herpes zoster ophthalmicus ...

The rash typically develops on one side of the body or face and forms blisters that scab over in 7–10 days, usually healing within two to four weeks. While shingles is more common in older adults, it ...

The Insurance Institute for Business and Home Safety in rural Chester County simulates strong hurricanes to test sample ...